Parse Biosciences

Parse Biosciences is a private life sciences tools company that has developed an innovative, instrument-free platform for single-cell RNA sequencing (scRNA-seq). Its Evercode technology uses split-pool combinatorial barcoding to allow experiments to scale from thousands to millions of cells with flexibility, addressing a key bottleneck in high-throughput genomics. The company offers a full product suite for whole transcriptome, immune profiling, and specialized applications, complemented by data analysis services and a recent launch of an FFPE-compatible kit. In early 2024, Parse was acquired by QIAGEN, significantly enhancing its commercial reach and resources.

Evercode™: An instrument-free, split-pool combinatorial barcoding platform for scalable single-cell RNA sequencing, applicable to fresh, frozen, fixed, and FFPE samples.

Parse competes in the single-cell analysis market primarily against 10x Genomics, the dominant player with its integrated Chromium instrument system. Other competitors include BD (Rhapsody), Singleron, and Fluxion Biosciences. Parse's key differentiation is its instrument-free, highly scalable workflow, which offers flexibility and lower upfront costs compared to closed, instrument-driven systems.